Toboroz
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
NCT05314998· 3. fázis· Universitaetsklinikum Heidelberg AöR· Forrás
Toboroz
Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
2022-500676-59-00· 2. fázis· GPOH gGmbH· Forrás
Toboroz
Using lab-grown mini-tumors from pancreatic cancer tissue to predict and improve post-surgery treatment for pancreatic cancer
2023-510490-34-00· 2. fázis· Universitaetsklinikum Ulm AöR· Forrás
Toboroz
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
2023-510356-23-00· 1. fázis· Novartis Pharma AG· Forrás
Toboroz
Assessment of the safety and efficacy of a hepatitis B vaccine in adult patients with hepatitis B
2023-507623-36-00· 1/2. fázis· Klinikum der Universitaet Muenchen AöR· Forrás
Toboroz
A contrast medium sparing strategy using automated Carbon Dioxide Injection during PERIpheral vascular interventions for PREVENTion of Major Adverse Kidney Events (MAKE): the PeriPREVENT randomized controlled trial
2024-512876-37-00· 3. fázis· Universitaet Leipzig· Forrás
Toboroz
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· 2. fázis· Eli Lilly & Co.· Forrás
Toboroz
Cyclosporine In Takotsubo Syndrome
NCT05946772· 2. fázis· University Hospital Heidelberg· Forrás
Toboroz
A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma
2024-514129-43-00· 2. fázis· Cancer Research UK· Forrás
Fut, nem toboroz
A Phase 2 diagnostic study with 68Ga-EVG321 in Patients with Small Cell Lung Cancer
2024-514584-25-00· 2. fázis· Evergreen Theragnostics Inc.· Forrás
Toboroz
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953· 3. fázis· Institut de Recherches Internationales Servier· Forrás
Fut, nem toboroz
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· 2/3. fázis· Eyebiotech Limited· Forrás
Fut, nem toboroz
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
2023-504724-25-00· 3. fázis· Kartos Therapeutics Inc.· Forrás
Toboroz
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808· 3. fázis· Gilead Sciences Inc.· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220· 3. fázis· Genmab· Forrás
Fut, nem toboroz
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06384976· 2. fázis· Kyverna Therapeutics· Forrás
Fut, nem toboroz
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498· 3. fázis· Kite, A Gilead Company· Forrás
Toboroz
Patient- and care-related benefits of amyloid PET imaging (ENABLE)
2023-503705-10-00· 4. fázis· Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.· Forrás
Toboroz
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178· 3. fázis· Genmab· Forrás
Toboroz
[18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer
2023-504026-19-01· 3. fázis· Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien GmbH· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· 3. fázis· Lysarc· Forrás
Toboroz
Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer
NCT06474806· 2. fázis· Curasight· Forrás
Toboroz
Anti-viral action against Type 1 diabetes autoimmunity
GPPAD-05-AVAnT1A
2023-507348-35-00· 4. fázis· Klinikum rechts der Isar der TU Muenchen AöR· Forrás
Fut, nem toboroz
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731· 3. fázis· Stealth BioTherapeutics Inc.· Forrás
Fut, nem toboroz
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942· 1. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
NCT06189833· 2. fázis· European Myeloma Network B.V.· Forrás
Fut, nem toboroz
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)
2023-506183-13-00· 2. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430· 1/2. fázis· Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Forrás
Toboroz
Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL
NCT06134492· 3. fázis· Jena University Hospital· Forrás
Fut, nem toboroz
Clinical and translational controlled study of Perampanel treatment around Surgery in patients with progressive glioblastoma (PerSurge)
2023-503938-52-00· 2. fázis· Universitaetsklinikum Heidelberg AöR· Forrás
Toboroz
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
2023-505121-14-00· 3. fázis· Janssen - Cilag International· Forrás
Toboroz
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411· 3. fázis· AbbVie· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491· 3. fázis· AstraZeneca· Forrás
Toboroz
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· 3. fázis· LeonaBio· Forrás
Fut, nem toboroz
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333· 2. fázis· AskBio Inc· Forrás
Toboroz
Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC
2023-503558-10-00· 3. fázis· Universitaetsmedizin Goettingen· Forrás
Toboroz
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
NCT06045689· 3. fázis· Bristol-Myers Squibb· Forrás
Fut, nem toboroz
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
NCT05713838· 2. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás
Showing 50 of 127.